Hong Shang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hong Shang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Hong Luan
Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
2 shared publicationsDong-Liang Man
Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, P.R. China
1 shared publicationGuo-Jiang Jin
Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, P.R. China
1 shared publicationHongyuan Liang
Department of Radiology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publicationLi-Ping Zhou
Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, P.R. China
1 shared publicationLiping Zhou
Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, PR China
1 shared publication
Latest Publications
- Open Access
- 20 February 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 5 (5) , 1256-1260
Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis
Sinomenine (SIN) is a bioactive component derived from a Chinese medicinal plant. Our previous studies demonstrated that SIN has cytotoxic effects on human lung cancer cells. However, the antitumor molecular mechanisms of SIN have yet to be elucidated in detail. In the present study, we further explored the effects of SIN on NCI-H460 human lung cancer cell viability and apoptosis and investigated the regulation and function of PI3K/Akt and ERK signaling pathways during SIN-induced apoptosis in various lung cancer cell lines. NCI-H460 cells were incubated with 200 µg/ml SIN for the indicated times (0, 24, 48 or 72 h). Cell viability was assessed by MTT assay. Akt, p-Akt, ERK1/2 and p-ERK1/2 protein levels were detected by western blotting, respectively. Two different selective inhibitors (LY294002 for the PI3K pathway; PD98059 for the MEK/ERK pathway) were used to characterize the relative roles of PI3K/Akt and ERK in SIN-induced apoptosis. Apoptosis was determined by flow cytometry. SIN inhibited the proliferation of NCI-H460 cells in a time-dependent manner, which was accompanied with significant activation of pAkt and pERK. LY294002 and PD98059 both significantly increased SIN-induced apoptosis in NCI-H460, NCI-H226 and NCI-H522 cells. Our findings suggest that the activation of the PI3K/Akt and ERK signaling pathways antagonize SIN-induced lung cancer cell apoptosis and molecules that inhibit these pathways should potentiate the effects of SIN. This study represents a significant step forward in our understanding of the signal transduction pathways associated with the apoptosis elicited by SIN.
- 20 February 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 5 (5) , 1256-1260
Open AccessActivation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis
Sinomenine (SIN) is a bioactive component derived from a Chinese medicinal plant. Our previous studies demonstrated that SIN has cytotoxic effects on human lung cancer cells. However, the antitumor molecular mechanisms of SIN have yet to be elucidated in detail. In the present study, we further explored the effects of SIN on NCI-H460 human lung cancer cell viability and apoptosis and investigated the regulation and function of PI3K/Akt and ERK signaling pathways during SIN-induced apoptosis in various lung cancer cell lines. NCI-H460 cells were incubated with 200 µg/ml SIN for the indicated times (0, 24, 48 or 72 h). Cell viability was assessed by MTT assay. Akt, p-Akt, ERK1/2 and p-ERK1/2 protein levels were detected by western blotting, respectively. Two different selective inhibitors (LY294002 for the PI3K pathway; PD98059 for the MEK/ERK pathway) were used to characterize the relative roles of PI3K/Akt and ERK in SIN-induced apoptosis. Apoptosis was determined by flow cytometry. SIN inhibited the proliferation of NCI-H460 cells in a time-dependent manner, which was accompanied with significant activation of pAkt and pERK. LY294002 and PD98059 both significantly increased SIN-induced apoptosis in NCI-H460, NCI-H226 and NCI-H522 cells. Our findings suggest that the activation of the PI3K/Akt and ERK signaling pathways antagonize SIN-induced lung cancer cell apoptosis and molecules that inhibit these pathways should potentiate the effects of SIN. This study represents a significant step forward in our understanding of the signal transduction pathways associated with the apoptosis elicited by SIN.
- Open Access
- 31 May 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (5) , 931-936
Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis
The aim of this study was to determine whether the vascular endothelial growth factor (VEGF) +936C/T polymorphism confers susceptibility to gastric cancer (GC) by conducting a meta-analysis. Publications addressing the association between the VEGF +936C/T polymorphism and GC risk were selected from the Pubmed, Embase and CBM databases. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed using RevMan 5.0.25 and STATA 9.2 software. From these data, the odds ratio (OR) with 95% confidence interval (CI) was calculated. Finally, 8 case-control studies were retrieved reporting a total of 2,131 gastrointestinal cancer patients and 2,670 controls. Meta-analysis results showed that there was no significant association between the VEGF +936C/T polymorphism and GC risk in all comparisons of the T allele vs. C allele (OR=1.08, 95% CI 0.90–1.30, P=0.42), CT+TT vs. CC (OR=1.08, 95% CI 0.87–1.34, P=0.49), TT vs. CC+CT (OR=1.14, 95% CI 0.85–1.53, P=0.37), TT vs. CC (OR=1.18, 95% CI 0.87–1.59, P=0.28) and TT vs. CT (OR=1.11, 95% CI 0.79–1.56, P=0.56). This meta-analysis confirms that there is a lack of association between the VEGF +936C/T polymorphism and GC risk.
- 31 May 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (5) , 931-936
Open AccessVascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis
The aim of this study was to determine whether the vascular endothelial growth factor (VEGF) +936C/T polymorphism confers susceptibility to gastric cancer (GC) by conducting a meta-analysis. Publications addressing the association between the VEGF +936C/T polymorphism and GC risk were selected from the Pubmed, Embase and CBM databases. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed using RevMan 5.0.25 and STATA 9.2 software. From these data, the odds ratio (OR) with 95% confidence interval (CI) was calculated. Finally, 8 case-control studies were retrieved reporting a total of 2,131 gastrointestinal cancer patients and 2,670 controls. Meta-analysis results showed that there was no significant association between the VEGF +936C/T polymorphism and GC risk in all comparisons of the T allele vs. C allele (OR=1.08, 95% CI 0.90–1.30, P=0.42), CT+TT vs. CC (OR=1.08, 95% CI 0.87–1.34, P=0.49), TT vs. CC+CT (OR=1.14, 95% CI 0.85–1.53, P=0.37), TT vs. CC (OR=1.18, 95% CI 0.87–1.59, P=0.28) and TT vs. CT (OR=1.11, 95% CI 0.79–1.56, P=0.56). This meta-analysis confirms that there is a lack of association between the VEGF +936C/T polymorphism and GC risk.